Fri, Jul 11, 2014, 5:20 AM EDT - U.S. Markets open in 4 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

blidskar 11 posts  |  Last Activity: May 27, 2014 10:05 AM Member since: Jul 18, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    stock split

    by stubby222 Feb 19, 2014 3:06 PM
    blidskar blidskar May 27, 2014 10:05 AM Flag

    Gee, they waited a month to start the selloff. When's the next RS? OTC is a scam. Short this pig to .25

    Sentiment: Strong Sell

  • Reply to

    Comments on Conference Call

    by plangleyxl May 13, 2014 12:04 PM
    blidskar blidskar May 19, 2014 12:35 AM Flag

    Alternately:
    It could be that Pfizer will get the Palatin's obesity peptide back on track to compete with Rythyms drug. Astrazeneca is the one who has it shelved right now. Rythym has no partner.
    Have to watch how it plays out.
    Either way it is still a program worth investing in. There are no big obesity drugs out there and they all want one. MC4 agonists have blockbuster potential..

    Sentiment: Buy

  • Reply to

    Comments on Conference Call

    by plangleyxl May 13, 2014 12:04 PM
    blidskar blidskar May 18, 2014 1:39 PM Flag

    Pfizer may shelve it, maybe not. If Pfizer gets Astrazeneca, Palatin would probably do better terminate the agreement. They may need to look for a competitor of Pfizers for developing an MC4 Obesity Drug.
    Palatin is probably trying to get a pulse on the intentions Pfizer would have for Palatin's MC4 Obesity program if they get to buy Aztrazeneca.

    Pfizer has invested a measly $8M in Rhythm Metabolic. Rythym has an MC4 Agonist for Obesity already in Phase II Trials (ClinicalTrials.gov Identifier NCT01749137).

    If Pfizer buys Astrazeneca and buys/backs Rythym, and RM-493 continues through clinical trials, Palatins MC4 Obesity program will probably need to go with a competitor to continue. Hopefully they can legally separate if needed.
    Rythym is still a self owned, private company, and has close ties with Merke, so it remains to be seen who they may partner with if at all.

    Sentiment: Buy

  • blidskar blidskar May 7, 2014 1:45 AM Flag

    Seems that would explain the PR Department lately. Went fishing and came back stoned.

    Sentiment: Buy

  • Astrazeneca has a division for this. UK-based research peptide and antibody manufacturer Cambridge Research Biochemicals (CRB). Since they already have an agreement with Aztrazeneca for development and manufacture of other Palatin owned peptides, why would they go with someone else?

    Sentiment: Buy

  • Reply to

    Stupid option agreement.

    by hypewatcher May 1, 2014 8:42 AM
    blidskar blidskar May 2, 2014 2:14 PM Flag

    If Palatin had left out the pr about the extension of deadline for the exercising of the option, and just announced when they did exercise it, it would have had a much better impact on investors. Now we have the Option Exercised, we wait for announcement of License Agreement for manufacturing Brem for FSD. And yes, they left out the deadline for the conclusion.
    It may indicate that Palatin is fully intent on an agreement with this company and does not care about setting a deadline.

    Sentiment: Buy

  • blidskar blidskar Apr 27, 2014 2:33 AM Flag

    For 650 patient enrollment, they need $78M and have about $18M.
    They have enough for salaries and preparation for Phase III clinical trial program with bremelanotide for female sexual dysfunction (FSD)

    From the Feb 14, 2014 10-Q Quarterly Report

    As of December 31, 2013, the Company’s cash, cash equivalents and short-term investments were $18.2 million. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including preparing for the Phase 3 clinical trial program with bremelanotide for female sexual dysfunction (FSD), preclinical development of its peptide melanocortin receptor-1 program, preclinical and clinical development of its PL-3994 program and preclinical development of other portfolio products. Management believes that the Phase 3 clinical trial program with bremelanotide will cost at least $78.0 million. The Company does not intend to initiate patient enrollment in the Phase 3 program unless the Company has adequate funds, or commitments for adequate funds, to complete the Phase 3 program. The Company intends to seek additional capital to support the Phase 3 program through collaborative arrangements on bremelanotide, public or private equity or debt financings, or other sources.

    Management believes that the Company’s existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) but not initiating patient enrollment, through at least March 31, 2015.

    Sentiment: Strong Buy

  • Reply to

    PR and Partner

    by hypewatcher Apr 24, 2014 5:07 PM
    blidskar blidskar Apr 25, 2014 12:07 PM Flag

    You are correct. 1M

    Sentiment: Strong Buy

  • Reply to

    PR and Partner

    by hypewatcher Apr 24, 2014 5:07 PM
    blidskar blidskar Apr 25, 2014 9:50 AM Flag

    Thinking that it is Palatin holding out as long as possible hoping to attract the partner with the deepest pockets, which is good for us too. The current one has shelled out 2M so far, so I think they want this. When you have lightning in a bottle, you go for the best deal. If they go with the current candidate, I will be happy. because we will all have deeper pockets from Bremelanotide sales.
    Glad they are talking to multiple US candidates, as the increases bargaining strength.

    Sentiment: Strong Buy

  • Reply to

    FLASH BUY $1.50 ON THE CLOSE FOR JOE & ZIG

    by johnb21400 Apr 21, 2014 2:23 PM
    blidskar blidskar Apr 21, 2014 2:51 PM Flag

    Links no allowed anymore it is on 'NJ dotcom' the reporter is Alexi Friedman from The Star-Ledger

    For Billie Jean O’Malley, the joy of sex disappeared, buried beneath the realities of life for a married mother of four young children.

    At 37, O’Malley had lost her sex drive. Counseling wasn’t the answer, she said, because except for a lack of sleep, life was good.

    A therapist, she believed, would just prescribe more sex.

    “I didn’t want to do that,” said the Columbus, Ohio resident. “I’d rather go to sleep, watch TV, cross stitch, whatever. I’ve had four kids so my body has changed. But I wanted it back.”

    So when O’Malley heard that New Jersey-based Palatin Technologies was recruiting for a clinical trial to test its drug treatment for female sexual dysfunction, she applied. And was accepted.

    The drug, she said, worked.

    “It cranked me right up there to a 7 or 8 out of 10, from 0 or 1,” O’Malley said. “I felt it throughout my whole body. I told my husband, ‘let’s lock up the kids.’”

    But when the 12-week clinical trial ended two years ago, so did the treatments. “I just wish the drug would come out now,” she said.

    Two years later, the drug, bremelanotide, remains in development and there is no approved medicine in the United States to treat female sexual dysfunction.

    For men, of course, it’s a different story. Viagra, Cialis, Levitra and other drugs that treat erectile dysfunction generate $5 billion in annual global sales. Viagra, the original little blue pill, was approved by the Food and Drug Administration more than 15 years ago.

    An estimated 8 million premenopausal adult women in the United States are distressed by their sexual problems, including 2 million who have sought formal treatment, according to a comprehensive study in the November 2008 issue of “Obstetrics & Gynecology.”

    Sentiment: Buy

  • Reply to

    FLASH BUY $1.50 ON THE CLOSE FOR JOE & ZIG

    by johnb21400 Apr 21, 2014 2:23 PM
    blidskar blidskar Apr 21, 2014 2:39 PM Flag

    New article yesterday "NJ biotech firm develops 'female Viagra' for women with low sexual desire"
    Quote from woman in the trials
    "It cranked me right up there to a 7 or 8 out of 10, from 0 or 1" -- Billie Jean O'Malley"
    Reporter talks to Spana some also.

    Sentiment: Buy

PFE
30.00-0.05(-0.17%)Jul 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.